$Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer$

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer

BACKGROUND Patients with recurrent and/or metastatic, radioactive iodine‐refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase inhibitor, is approved by the US Food and Drug Administration for the treatment of radioactive iodine‐refractory thyroid carcinoma, although...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2017-11, Vol.123 (21), p.4114-4121
Hauptverfasser:	Sherman, Eric J., Dunn, Lara A., Ho, Alan L., Baxi, Shrujal S., Ghossein, Ronald A., Fury, Matthew G., Haque, Sofia, Sima, Cami S., Cullen, Grace, Fagin, James A., Pfister, David G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma, Follicular - drug therapy Adenocarcinoma, Follicular - genetics Adenocarcinoma, Follicular - pathology Adenocarcinoma, Follicular - radiotherapy Adult Aged Aged, 80 and over anaplastic thyroid cancer Anemia Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Background radiation Cancer Cancer therapies Chemotherapy Cytotoxicity Disease-Free Survival Drug Administration Schedule Enzyme inhibitors Fatigue Female Humans Hyperglycemia Inhibitor drugs Inhibitors Intravenous administration Iodine Iodine Radioisotopes - therapeutic use Male mammalian target of rapamycin (mTOR) inhibition Metastases Metastasis Middle Aged Mucositis Mutation Niacinamide - administration & dosage Niacinamide - adverse effects Niacinamide - analogs & derivatives Oncology Patients Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Proto-Oncogene Proteins B-raf - genetics Quality Radiation Tolerance Rapamycin Response rates Sirolimus - administration & dosage Sirolimus - adverse effects Sirolimus - analogs & derivatives sorafenib Targeted cancer therapy Thyroid Thyroid cancer Thyroid carcinoma Thyroid Neoplasms - drug therapy Thyroid Neoplasms - genetics Thyroid Neoplasms - pathology Thyroid Neoplasms - radiotherapy TOR protein Toxicity Treatment Outcome v‐Raf murine sarcoma viral oncogene homolog B (BRAF) mutation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!